Evidence map›Paper›PMID 40925954›Full record

ArticleNature cell biology2025

CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8

Tongsen Zheng, Chujie Ding, Shihui Lai, Yang Gao, Cheng Lyu, Caiqi Liu, Jiaqi Shi, Xiaobo Li, Mingwei Li, Hongxue Meng and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Morula-derived trophectoderm stem cells.Nature cell biology · 2025
    Article
  10. CD160Nature cell biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tongsen Zheng *Key Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China. zhengtongsen@hrbmu.edu.cn.ORCID http://orcid.org/0000-0002-7539-3924
Chujie Ding *Key Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.ORCID http://orcid.org/0000-0002-2461-7756
Shihui Lai *Key Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.ORCID http://orcid.org/0009-0007-3806-6442
Yang Gao *Key Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.ORCID http://orcid.org/0000-0002-7040-5260
Cheng LyuSchool of Basic Medical Sciences, Harbin Medical University, Harbin, China.ORCID http://orcid.org/0009-0005-6612-8204
Caiqi LiuKey Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.
Jiaqi ShiKey Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.ORCID http://orcid.org/0000-0002-8458-2364
Xiaobo LiDepartment of Pathology, Harbin Medical University, Harbin, China.
Mingwei LiKey Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.
Hongxue MengDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.ORCID http://orcid.org/0000-0002-1831-2737
Mingqi LiDepartment of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Yingjian LiangDepartments of General Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, China.
Sheng TaiDepartment of Hepatic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Liang ChengCollege of Bioinformatics Science and Technology, NHC Key Laboratory of Molecular Probe and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin, China.ORCID http://orcid.org/0000-0002-6665-6710
Yan ZhangKey Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.
Li LiDepartment of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Peng HanDepartment of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Bin SunResearch Center for Pharmacoinformatics (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin, China.
Te LiuResearch Center for Pharmacoinformatics (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy, Harbin Medical University, Harbin, China.ORCID http://orcid.org/0009-0002-3205-0988
Feng GengKey Laboratory of Molecular Oncology of Heilongjiang Province, Harbin, China.ORCID http://orcid.org/0000-0002-2985-0629
Dapeng HaoSchool of Basic Medical Sciences, Harbin Medical University, Harbin, China. dapenghao@hrbmu.edu.cn.ORCID http://orcid.org/0000-0002-9043-371X
Xue ZhangNHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin, China. xuezhang@hrbmu.edu.cn.ORCID http://orcid.org/0009-0004-0249-0581

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The colon exhibits higher propensity for tumour development than ileum. However, the role of immune microenvironment differences in driving this disparity remains unclear. Here, by comparing paired ileum and colon samples from patients with colorectal cancer (CRC) and healthy donors, we identified ileum-enriched CD160

Indexed as

Antigens, CDCD8-Positive T-LymphocytesColorectal NeoplasmsDrug Resistance, NeoplasmGPI-Linked ProteinsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorReceptors, ImmunologicAnimalsCell Line, TumorFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiceAntigens, CDCD160 protein, humanGPI-Linked ProteinsImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Immunologic

Identifiers

PMID40925954

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.